Patents by Inventor Ravindra W. Tejwani

Ravindra W. Tejwani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent number: 9198925
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: December 1, 2015
    Assignee: AstraZeneca AB
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
    Publication number: 20140243262
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent number: 8716251
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent number: 8361972
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: January 29, 2013
    Assignee: Bristol Myers-Squibb Company
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Pharmaceutical Formulations Containing an SGLT2 Inhibitor
    Publication number: 20120263786
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Application
    Filed: June 21, 2012
    Publication date: October 18, 2012
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent number: 8221786
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: July 17, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Pharmaceutical Formulations Containing an SGLT2 Inhibitor
    Publication number: 20110064801
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Application
    Filed: November 18, 2010
    Publication date: March 17, 2011
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent number: 7851502
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: December 14, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts
    Patent number: 7659262
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: February 9, 2010
    Assignee: Bristol-Myers Squibb Co.
    Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
  • Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
    Patent number: 7659261
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: February 9, 2010
    Assignee: Bristol-Myers Squibb Co.
    Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
  • Combretastatin A-4 Phosphate Prodrug Mono- and Di- Organic Amine Salts, Mono- and Di- Amino Acid Salts, and Mono- and Di- Amino Acid Ester Salts
    Publication number: 20090186857
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Application
    Filed: November 5, 2008
    Publication date: July 23, 2009
    Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
  • Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts
    Patent number: 7524832
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: April 28, 2009
    Assignee: Bristol-Myers Squibb Co.
    Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
  • PHARMACEUTICAL FORMULATION CONTAINING AN SGLT2 INHIBITOR
    Publication number: 20080234366
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Application
    Filed: March 21, 2008
    Publication date: September 25, 2008
    Applicant: Bristol-Myers Squibb
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
    Patent number: 6855702
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: February 15, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
  • Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
    Publication number: 20040054212
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Application
    Filed: September 10, 2003
    Publication date: March 18, 2004
    Applicant: Bristol-Myers Squibb Company
    Inventors: John J. Venit, Mandar V. Dall, Manisha M. Dall, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
  • Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
    Patent number: 6670344
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Grant
    Filed: September 11, 2001
    Date of Patent: December 30, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani
  • Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono--and di-amino acid salts, and mono-and di-amino acid ester salts
    Publication number: 20020072507
    Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.
    Type: Application
    Filed: September 11, 2001
    Publication date: June 13, 2002
    Inventors: John J. Venit, Mandar V. Dali, Manisha M. Dali, Yande Huang, Charles E. Dahlheim, Ravindra W. Tejwani